IBIDI GMBH

Their core work

ibidi is a German SME based near Munich that develops and manufactures microfluidic cell-based assay systems — essentially specialized lab tools that let researchers observe living cells under controlled flow conditions. Their core product line includes flow chambers, slides, and imaging-compatible devices used in cell biology, drug testing, and quality control of cell therapies. Within EU projects, they contribute microfluidic device expertise, validation capabilities, and quality management for scaling lab-grade technologies toward industrial production.

What they specialise in

How they've shifted over time

ibidi's early H2020 work (2015-2018) centered on fundamental cell biology research and early-stage product concepts — participating in a training network on cell motility (InCeM) and coordinating a small SME Instrument Phase 1 feasibility study for cell therapy quality control (Quality2Cells). Their most recent project (NextGenMicrofluidics, 2020-2025) marks a clear pivot toward industrial-scale manufacturing, with emphasis on nano-enabled surfaces, roll-to-roll production, and regulatory pathways. The trajectory shows a company moving from research participation toward production-ready technology and commercialization.

ibidi is moving from a research-tool supplier toward an industrial partner capable of scaling microfluidic technologies from lab to production line, with growing attention to regulation and market readiness.

How they like to work

ibidi operates mostly as a specialist participant (2 of 3 projects), contributing domain-specific microfluidic expertise to larger consortia. Their one coordination role was a small SME Instrument Phase 1 project (€50K), suggesting they are comfortable leading focused feasibility studies but primarily join larger teams where they fill a specific technical niche. With 51 unique partners across 14 countries, they are well-connected for an SME of their size and open to diverse international collaborations.

ibidi has collaborated with 51 distinct partners across 14 countries, a substantial network for a small company. Their partnerships span both academic institutions (InCeM training network) and industrial consortia (NextGenMicrofluidics), indicating comfort working across research and industry environments.

What sets them apart

ibidi occupies a specific niche as a commercial microfluidics company that bridges cell biology research and industrial manufacturing. Unlike pure research groups, they bring product development experience, quality management systems, and a direct path to market. For consortium builders, they offer a rare combination: deep technical knowledge in microfluidic devices plus real-world experience with validation, regulation, and commercialization — making them a credible partner for projects that need to demonstrate market viability.

Highlights from their portfolio

• NextGenMicrofluidics
  Their largest funded project (€432K), focused on scaling microfluidic devices to industrial production using nano-enabled surfaces — represents their strategic direction.
• Quality2Cells
  Their only coordinator role, an SME Instrument Phase 1 project developing a TimeLapseReader for immune cell quality control — shows their product innovation capability.